Medtronic's pain and ICD devices:
This article was originally published in Clinica
Executive Summary
Medtronic can now sell both its next-generation neurostimulation implant for chronic pain relief and a new implantable cardioverter- defibrillator (ICD). The SynergyPlus+ "pain pacemaker" is designed to give patients more control over the delivery of stimulation that blocks pain signals from reaching the brain while performing a variety of daily activities. It has the greatest number of programme options - up to 26 - available of any non-rechargeable neurostimulation system on the market and provides a level of therapy customisation that may result in fewer physician follow-up visits, claims the firm. The EnTrust single- and dual-chamber ICDs employ Medtronic's ATP During Charging feature, which automatically uses pacing pulses to painlessly stop fast, dangerous heartbeats, while concurrently preparing to deliver a shock if needed, with no delay.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.